Dimensional Fund Advisors LP boosted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 6.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,459,427 shares of the biopharmaceutical company's stock after purchasing an additional 87,979 shares during the period. Dimensional Fund Advisors LP owned about 2.37% of Xencor worth $27,628,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of the business. Parallel Advisors LLC boosted its position in Xencor by 303.9% during the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 1,015 shares during the period. GAMMA Investing LLC raised its stake in shares of Xencor by 153.7% during the first quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company's stock valued at $48,000 after acquiring an additional 1,316 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Xencor during the second quarter worth $154,000. Acadian Asset Management LLC bought a new stake in shares of Xencor in the first quarter worth $206,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Xencor in the first quarter worth $229,000.
Xencor Stock Performance
Shares of Xencor stock traded up $0.02 during mid-day trading on Thursday, hitting $19.48. 290,923 shares of the stock were exchanged, compared to its average volume of 630,062. The company has a market capitalization of $1.20 billion, a P/E ratio of -8.89 and a beta of 0.66. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.92 and a current ratio of 6.92. The company has a 50-day simple moving average of $18.62 and a 200 day simple moving average of $20.25. Xencor, Inc. has a 12 month low of $15.31 and a 12 month high of $26.84.
Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.25). The company had revenue of $16.96 million for the quarter, compared to the consensus estimate of $21.13 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. Xencor's quarterly revenue was down 62.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.37) EPS. Sell-side analysts anticipate that Xencor, Inc. will post -4.15 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, VP John R. Desjarlais sold 36,329 shares of Xencor stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $18.32, for a total value of $665,547.28. Following the completion of the transaction, the vice president now owns 192,319 shares in the company, valued at $3,523,284.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 5.23% of the stock is currently owned by insiders.
Analyst Ratings Changes
Several analysts recently commented on XNCR shares. JPMorgan Chase & Co. reduced their target price on Xencor from $30.00 to $27.00 and set an "overweight" rating on the stock in a report on Wednesday, July 31st. Wedbush reiterated an "outperform" rating and set a $34.00 price objective on shares of Xencor in a research report on Monday, September 9th. BMO Capital Markets restated an "outperform" rating and issued a $32.00 target price on shares of Xencor in a report on Tuesday, August 6th. Raymond James decreased their price target on Xencor from $58.00 to $40.00 and set a "strong-buy" rating for the company in a report on Friday, June 14th. Finally, Royal Bank of Canada lifted their price objective on Xencor from $31.00 to $34.00 and gave the stock an "outperform" rating in a research report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Xencor has a consensus rating of "Moderate Buy" and an average target price of $34.78.
Check Out Our Latest Stock Analysis on XNCR
About Xencor
(
Free Report)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
See Also
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
